Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 3, 2008, Pages 416-421

  Urban, T J ^a   Brown, C ^a   Castro, R A ^a   Shah, N ^a   Mercer, R ^a   Huang, Y ^a   Brett, C M ^a   Burchard, E G ^a   Giacomini, K M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; COMPLEMENTARY DNA; GABAPENTIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 1L503F; SODIUM ION; UNCLASSIFIED DRUG;

ADULT; ALLELE; APICAL MEMBRANE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG PROTEIN BINDING; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE CELL; KIDNEY CELL; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MALE; MEMBRANE TRANSPORT; NEUROPATHY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AMINES; CELL LINE; COHORT STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TUBULES; LEUCINE; MALE; METABOLIC CLEARANCE RATE; ORGANIC CATION TRANSPORTER 1; PHENYLALANINE; POLYMORPHISM, GENETIC; REFERENCE VALUES; VARIATION (GENETICS);

EID: 39449103552     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100271     Document Type: Article

References (27)

1. Mclean, M.J. Gabapentin in the management of convulsive disorders. Epilepsia 40 (suppl. 6): S39-S50 (1999).
2. Backonja, M. & Glanzman, R.L. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin. Ther. 25, 81-104 (2003).
3. Ettinger, A.B. & Argoff, C.E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4, 75-83 (2007).
4. Evins, A.E. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J. Clin. Psychiatry 64 (suppl. 8): 9-14 (2003).
5. Mathew, N.T. et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41, 119-128 (2001).
6. Mclean, M.J. Clinical pharmacokinetics of gabapentin. Neurology 44 (suppl. 5): S17-S22 (1994).
7. Ouellet, D., Bockbrader, H.N., Wesche, D.L., Shapiro, D.Y. & Garofalo, E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 47, 229-241 (2001).
8. Boyd, R.A., Turck, D., Abel, R.B., Sedman, A.J. & Bockbrader, H.N. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40, 474-479 (1999).
9. Neurontin [package insert] (Pfizer, New York, NY, 2005).
10. Stewart, B.H., Kugler, A.R., Thompson, P.R. & Bockbrader, H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10, 276-281 (1993).
11. Gidal, B.E. et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31, 91-99 (1998).
12. Gidal, B.E., Radulovic, L.L., Kruger, S., Rutecki, P., Pitterle, M. & Bockbrader, H.N. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40, 123-127 (2000).
13. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283-289 (1998).
14. Kalow, W., Endrenyi, L. & Tang, B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 58, 281-284 (1999).
15. Uchino, H. et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol. 61, 729-737 (2002).
16. Peltekova, V.D. et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat. Genet. 36, 471-475 (2004).
17. Taubert, D., Grimberg, G., Jung, N., Rubbert, A. & Schomig, E. Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn's disease. Gut 54, 1505-1506 (2005).
18. Grundemann, D. et al. Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. USA 102, 5256-5261 (2005).
19. Cockcroft, D.W. & Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
20. Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. & Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461-470 (1999).
21. Ieiri, I., Takane, H., Hirota, T., Otsubo, K. & Higuchi, S. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin. Drug Metab. Toxicol. 2, 651-674 (2006).
22. Tamai, I. et al. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol. Pharm. 1, 57-66 (2004).
23. Yokogawa, K. et al. Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. J. Pharmacol. Exp. Ther. 289, 224-230 (1999).
24. Ohashi, R. et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol. 59, 358-366 (2001).
25. Leabman, M.K. et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl. Acad. Sci. USA 100, 5896-5901 (2003).
26. Urban, T.J. et al. Functional genomics of membrane transporters in human populations. Genome Res. 16, 223-230 (2006).
27. Urban, T.J., Giacomini, K.M. & Risch, N. Haplotype structure and ethnic-specific allele frequencies at the OCTN locus: implications for the genetics of Crohn's disease. Inflamm. Bowel Dis. 11, 78-79 (2005).